For example, (S)-2,3-dihydro-1,4-benzodioxin-2-carboxylic acid is an intermediate for doxazosin mesylate, a primary drug used for the treatment of hypertension and benign prostatic hyperplasia (BPH) [3], 2,3-dihydro-2-hydroxymethyl-1,4-benzodioxin, a prostaglandin D2 receptor antagonist [4] and N-[2,4-oxo-1,3-thiazolidin-3-yl]-2,3-dihydro-1,4-benzodioxin-2-carboxamide, which has antihepatotoxic activity [5]. Here, PTGDR is linked to benign prostatic hyperplasia.